comprative study between tarunyapidikaharlepd and manjistha churna on yuvanpidika

A STUDY OF RAKTA DHATU TO EVALUATION THE EFFICACY OF TARUNYAPIDIKAHAR LEPA AND MANJISTHA CHURNA IN MANAGEMENT YUVANPIDIKA - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/086442

Enrollment

Registered

2025-05-06

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L988- Other specified disorders of the skin and subcutaneous tissue

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Subjects of females will be taken. Age between 16 to 30 years. Patient with signs and symptoms of Yuvanpidikaha(O-35) by Acharya Sushruta Individuals willing to participate in the study.

Exclusion criteria

Exclusion criteria: With a present history of chronic diseases of the skin like Psoriasis, Vitiligo, Dermatitis etc. Patients with known cases of genetic skin disorder, chronic systemic diseases, Gravida and lactating women, or any organ failure. Patient who is chemically exposed, and burn patches.

Design outcomes

Primary

Measure	Time frame
The primary outcome of the research study is to evaluate and compare the efficacy of Tarunyapidikahar Lepa and Manjistha Churna in the management of Yuvanpidika (O-35), as measured by clinical improvements in signs and symptoms such as the number of eruptions (Pidaka), itching (Kandu), pain (Ruja), burning sensation (Daha), and discharge (Strava) over a 45-day treatment period. Timepoint: 45 days	—

Secondary

Measure	Time frame
1. To elucidate the physiological concept of Rakta Dhatu in relation to Yuvanpidika as per Ayurvedic texts, enhancing the understanding of its role in the disease pathology. 2. To establish Tarunyapidikahar Lepa and Manjistha Churna as safe and cost-effective treatment options for Yuvanpidika, assessed through clinical outcomes, adverse drug reaction (ADR) monitoring, and patient compliance during the study.Timepoint: 45 days	—

Measure

Time frame

1. To elucidate the physiological concept of Rakta Dhatu in relation to Yuvanpidika as per Ayurvedic texts, enhancing the understanding of its role in the disease pathology. 2. To establish Tarunyapidikahar Lepa and Manjistha Churna as safe and cost-effective treatment options for Yuvanpidika, assessed through clinical outcomes, adverse drug reaction (ADR) monitoring, and patient compliance during the study.Timepoint: 45 days

—

Countries

India

Contacts

Public Contactprof Dr Dinesh Chandra Sharma

PGIA Jodhpur, Rajasthan

dr_dcsharma@yahoo.com706273100

Outcome results